Moss, 9.5.2019
Gentian Diagnostics AS announces its results for the first quarter of 2018. The highlights include:
• Good start to the new fiscal year with sales revenues of MNOK 10.6 for the quarter.
• Record sales achieved for fCAL®turbo, our innovative biomarker for the diagnosis of inflammatory bowel disease.
• New scientific study results confirm GCAL as a promising biomarker for the diagnosis of bacterial infections.
Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525